Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4413MR)

This product GTTS-WQ4413MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4413MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11931MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ1864MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ15749MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ1122MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ10329MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ2277MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ15727MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ7118MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW